Uses/Indications: Prevention or minimization of recurrence of aortic thromboembolism associated with heart diseases such as cardiomyopathy and mitral valve dysplasia.
Studies: 1. In 2013, a large scale multi-center prospective randomized trial known as FAT-CAT (Feline Arterial Thromboembolism: Clopidogrel vs. Aspirin Trial) results were released determining clopidogrel offered longer survival rates when compared to aspirin in cats with recurrent thromboembolism. 72 cats were enrolled and randomly assigned to receive: (AG)-Aspirin 81mg PO every 3 days (36 cats) or (CG)-Clopidogrel 18.75mg PO Daily (36 cats). For the initial 12 month study period, median survival time to the primary endpoint (recurrent CATE event) was 192 days in the aspirin group and > 365 days in the clopidogrel group (443 days). Clopidogrel also showed superiority when compared to aspirin in all of the secondary endpoints such as all-cause mortality (AG-116 days vs. CG-248 days), and cardiac death (AG-128 days vs. CG-346 days).
Adverse Effects: Nausea (vomiting) and Anorexia (loss of appetite), potential risk for excessive bleeding, black and tarry stools
Dosing: 18.75mg PO Daily (dose is not based on weight) **Liquid Suspensions stable up to 60 days**
Monitoring Parameters: Sudden and rapid weight Loss, Any signs/symptoms of excessive bleeding